On August 20, 2020, the United States Drug Enforcement Administration (“DEA”) issued an interim final rule (“IFR”) pertaining to the classifications of marijuana and hemp under the federal Controlled Substances Act (“CSA”) in light of the 2018 Agricultural Improvement Act (“AIA”). Because the DEA … Read more about Is the DEA Coming for the Hemp Industry After All?
Since the start of the ongoing outbreak, the cannabis industry has been the source of some debate as stakeholders and active consumers attempt to understand COVID-19’s far-reaching effects. Pulmonologists and lung experts have cautioned that inhaled smoke from combusted plant material – be it … Read more about Evidence Suggests CBD Potential in Treating COVID-19
A recently passed amendment to the National Defense Authorization Act (“NDAA”) could allow military service members to use cannabidiol (“CBD”) and other hemp-derived products. The measure, sponsored by veteran Rep. Tulsi Gabbard (D-HI), was introduced on July 20, 2020, and was passed in the House of … Read more about Amendment to NDAA Would Allow Military Service Members to Use CBD Products
On July 8, 2020, the U.S. Food and Drug Administration (“FDA”) delivered the results of its most comprehensive sampling study on the current cannabidiol (“CBD”) marketplace to the U.S. House Committee on Appropriations and the U.S. Senate Committee on Appropriations.1 Congress mandated FDA to … Read more about FDA Delivers Latest CBD Study to Congress
On May 14, The Rodman Law Group held an internal webinar to analyze the variety of intellectual property ("IP") rights available to cannabis businesses and entrepreneurs including federal and state trademark protection, patents, and copyright. Moderated by firm Associate Attorney Rebecca Spence, … Read more about Firm Webinar: Intellectual Property and Cannabis
On April 24, 2020, the Federal Trade Commission (“FTC”) filed a complaint in federal court as well as an administrative complaint against California-based marketer, Whole Leaf Organics for its unsubstantiated product claims.1 The company sells Thrive, a supplement consisting mainly of vitamin C and … Read more about FTC Sues Company for Unsubstantiated Claims
COVID-19 has permeated virtually every aspect of our daily society, affecting millions of people and businesses across the country, and countless others overseas. In light of the impact of COVID19 and the confusion about the various aid and stimulus packages offered by the federal government, The … Read more about Firm Q&A: COVID’s Impact
On Monday, April 6, GW Pharmaceuticals revealed that the company had received notice from the U.S. Drug Enforcement Administration (“DEA”) stating that its drug Epidiolex was no longer subject to the requirements of the Controlled Substances Act (“CSA”). In a company release announcing the agency … Read more about DEA Removes CBD from Controlled Substances Act